In short
Clinical trials are investigating Azd3470 in people with advanced solid tumours that are MTAP deficient. The studies are looking at safety, tolerability, and the recommended dose for later testing, both as a single treatment and with anti-cancer medicines.
Key points
- Clinical trials of Azd3470 are studying people with advanced or metastatic solid tumours that are MTAP deficient. The main trial listed is a Phase 1 study, which means it is focused on safety, tolerability, and dose finding. Researchers are testing Azd3470 as a single treatment and also in combination with anti-cancer agents. The trial will measure adverse events, serious adverse events, and dose-limiting toxicities. The study is authorised and plans to include 234 participants. The goal is to find the recommended phase 2 dose for future research.
Trial overview
The listed study is an interventional clinical trial, which means researchers give a treatment and then watch what happens. It is studying Azd3470 in people with advanced/metastatic solid tumors that are MTAP deficient. The trial is authorised and plans to include 234 participants.
Who can join the study
This study is for participants with advanced or metastatic solid tumors that are MTAP deficient. In simple terms, this means the cancer has grown beyond its original site, and the tumor has a specific missing feature called MTAP.
The trial data does not give more detailed eligibility rules, so the main group described is people with this cancer type and tumor feature.
What is being tested
The brief summary says the study aims to assess the safety and tolerability of Azd3470 and to find the recommended phase 2 dose (RP2D). RP2D means the dose that may be chosen for later studies after early testing.
Azd3470 is being tested as monotherapy, meaning by itself, and also in combination with anti-cancer agents. This helps researchers compare how the treatment works alone and together with other cancer medicines.
Study phase and size
The trial is in Phase 1. Phase 1 studies usually look first at safety, side effects, and dose selection rather than proving benefit.
The planned enrollment is 234 people. That number gives an idea of how many participants the researchers hope to include in the study.
What researchers measure
The main outcomes are adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLT). These are ways to track unwanted medical problems during the study, from common side effects to more serious problems that can limit treatment.
Researchers will count these events by system organ class and preferred term, which is a standard way to group and name medical problems in a clinical trial. This helps the team understand which side effects happen and how often they occur.
Why this study matters
This trial is an early step in learning whether Azd3470 can be studied further in people with a specific type of advanced cancer. The main goal is not yet to prove long-term benefit, but to gather early information that can guide later research.
Because the study includes both single-treatment and combination-treatment parts, it may help researchers understand whether Azd3470 should move forward alone, with other anti-cancer agents, or both.